BioRestorative Therapies, Inc. (BRTX): Valuation
TTM figures as of March 31, 2026
BioRestorative Therapies, Inc. trades at a -322.64% free-cash-flow yield. That FCF yield is higher than 92% of its own month-end history back to 2012.
Earnings yield -299.83%. Shareholder yield -54.57%. Piotroski F-score 4 of 9.
165 month-end valuation observations are on file, starting December 2012.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is BRTX cheap versus its own history?
BioRestorative Therapies, Inc. trades at a -322.64% free-cash-flow yield. That FCF yield is higher than 92% of its own month-end history back to 2012.
What is BRTX's free-cash-flow yield?
BioRestorative Therapies, Inc. currently yields -322.64% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.